Non-Clinical Evaluations of Deucravacitinib and Janus Kinase Inhibitor Specificity in Inflammatory or Homeostatic Pathways

被引：0
|
作者：
Johnson, Brandon [1 ]
Koenitzer, Jennifer [1 ]
Schafer, Peter [1 ]
Catlett, Ian M. [1 ]
机构：
[1] Bristol Myers Squibb, Princeton, NJ USA
来源：
ARTHRITIS & RHEUMATOLOGY | 2022年 / 74卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
0584
引用
收藏
页码：1179 / 1180
页数：2
相关论文
共 50 条
  • [1] Nonclinical evaluations of deucravacitinib and Janus kinase inhibitors in homeostatic and inflammatory pathways
    Johnson, Brandon
    Cheng, Lihong
    Koenitzer, Jennifer
    Catlett, Ian M.
    Schafer, Peter
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [2] Selectivity Profile of the Tyrosine Kinase 2 Inhibitor Deucravacitinib Compared with Janus Kinase 1/2/3 Inhibitors
    Anjaneya Chimalakonda
    James Burke
    Lihong Cheng
    Ian Catlett
    Michael Tagen
    Qihong Zhao
    Aditya Patel
    Jun Shen
    Ihab G. Girgis
    Subhashis Banerjee
    John Throup
    Dermatology and Therapy, 2021, 11 : 1763 - 1776
  • [3] Selectivity Profile of the Tyrosine Kinase 2 Inhibitor Deucravacitinib Compared with Janus Kinase 1/2/3 Inhibitors
    Chimalakonda, Anjaneya
    Burke, James
    Cheng, Lihong
    Catlett, Ian
    Tagen, Michael
    Zhao, Qihong
    Patel, Aditya
    Shen, Jun
    Girgis, Ihab G.
    Banerjee, Subhashis
    Throup, John
    DERMATOLOGY AND THERAPY, 2021, 11 (05) : 1763 - 1776
  • [4] Biomarker Changes with Selective Tyrosine Kinase 2 Inhibitor, Deucravacitinib, in PsA: Effects on Disease Markers and Tyrosine Kinase 2-versus Janus Kinase 1/2/3-mediated Pathways
    FitzGerald, Oliver
    Gladman, Dafna
    Mease, Philip
    Ritchlin, Christopher
    Smolen, Josef
    Gao, Lu
    Hu, Sarah
    Nowak, Miroslawa
    Banerjee, Subhashis
    Catlett, Ian
    Guo, Xiang
    ARTHRITIS & RHEUMATOLOGY, 2021, 73 : 1013 - 1015
  • [5] Patient Perspectives on Janus Kinase Inhibitor Use in the Treatment of Inflammatory Arthritis
    De Souza, Savia
    Bassett, Andrew
    Williams, Ruth
    Nikiphorou, Elena
    ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 373 - 376
  • [6] Content Specificity of Threat Interpretation in Anxious and Non-Clinical Children
    Micco, Jamie A.
    Hirshfeld-Becker, Dina R.
    Henin, Aude
    Ehrenreich-May, Jill
    COGNITIVE THERAPY AND RESEARCH, 2013, 37 (01) : 78 - 88
  • [7] Content Specificity of Threat Interpretation in Anxious and Non-Clinical Children
    Jamie A. Micco
    Dina R. Hirshfeld-Becker
    Aude Henin
    Jill Ehrenreich-May
    Cognitive Therapy and Research, 2013, 37 : 78 - 88
  • [8] Clinical Pharmacology of Janus Kinase Inhibitors in Inflammatory Bowel Disease
    Lefevre, Pavine L. C.
    Vande Casteele, Niels
    JOURNAL OF CROHNS & COLITIS, 2020, 14 : S725 - S736
  • [9] Non-clinical pharmacokinetics, distribution and excretion of SNS-314, a novel, selective aurora kinase inhibitor
    Evanchik, M. J.
    Hoch, U.
    Fuchs-Knotts, T.
    Silverman, J. A.
    EJC SUPPLEMENTS, 2007, 5 (04): : 78 - 78
  • [10] Preclinical to Clinical Translation of Tofacitinib, a Janus Kinase Inhibitor, in Rheumatoid Arthritis
    Dowty, Martin E.
    Jesson, Michael I.
    Ghosh, Sarbani
    Lee, Jamie
    Meyer, Debra M.
    Krishnaswami, Sriram
    Kishore, Nandini
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2014, 348 (01): : 165 - 173
12345